# US 5,703,047 A · Methods and treatments for corneal healing with growth factors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,703,047 A
- Document ID: US5703047A
- Status: Granted
- Kind: A
- Application number: 08/400,323
- Filed: 1995-03-09
- Granted: 1997-12-30
- Earliest claimed: 1992-09-21
- Assignees: Board of Regents, The University of Texas System
- Inventors: Steven E. Wilson
- Web page: https://patentgrep.com/patent/US5703047A

## CPC

- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to the use of hepatocyte and keratinocyte growth factors for stimulating the proliferation and motility of corneal cells in vivo and in vitro. Also disclosed is the use of these factors for maintaining the viability of corneal cells during or after ocular surgery and during corneal preservation in storage medium prior to transplant. Polymerase chain reaction amplification has demonstrated that corneal epithelial and endothelial cells in vitro and ex vivo corneal epithelium produce messenger RNA coding for hepatocyte growth factor, hepatocyte growth factor receptor, keratinocyte growth factor, and keratinocyte growth factor receptor. Several growth factors were found to inhibit the differentiation of corneal epithelial cells as measured by decreased expression of keratin K3. Methods for treating ocular dry eye diseases are presented.

## Claims

### Claim 1

A method of inhibiting corneal epithelial cell differentiation comprising contacting a corneal cell with an amount of a growth factor selected from the group consisting of hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF) effective to inhibit corneal cell differentiation.

### Claim 2 (depends on 1)

The method of claim 1 wherein the dry eye ocular disease is keratoconjunctivitis sicca.

### Claim 3 (depends on 1)

The method of claim 1 wherein the cell is contacted sequentially with two growth factors from said group.

### Claim 4 (depends on 1)

The method of claim 1 wherein the corneal cell is in a mammal.

### Claim 5 (depends on 4)

The method of claim 4 wherein the corneal cell differentiation is associated with dry eye ocular disease.

### Claim 6 (depends on 5)

The method of claim 5 wherein the dry eye ocular disease is further identified as keratoconjunctivitis sicca.

### Claim 7 (depends on 1)

The method of claim 1 wherein the cell is contacted simultaneously with hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF).

### Claim 8 (depends on 6)

The method of claim 6 further including combining the growth factor with a timed release system.

### Claim 9 (depends on 8)

The method of claim 8 wherein the timed release delivery system is a biodegradable polymer encapsulating the growth factor.

### Claim 10 (depends on 9)

The method of claim 9 wherein the biodegradable polymer is a microcapsule.

### Claim 11 (depends on 5)

The method of claim 5 further comprising topically administering the growth factor.